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Abstract.  
Mathematical modelling of tumor growth is one of the most useful and 
inexpensive approaches to determine and predict the stage, size and progression 
of tumors in realistic geometries. Moreover, these models has been used to get 
an insight into cancer growth and invasion and in the analysis of tumor size and 
geometry for applications in cancer treatment and surgical planning. The present 
revision attempts to present a general perspective of the use of models based on 
reaction-diffusion equations not only for the description of tumor growth in 
gliomas, addressing for  processes such as tumor heterogeneity, hypoxia, 
dormancy and necrosis, but also its potential use as a tool in designing optimized 
and patient specific therapies. 
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Resumen. 
El modelaje matemático del crecimiento tumoral representa uno de los métodos 
más útiles y de más bajo costo para determinar y predecir tanto el estadio, 
tamaño y evolución de los tumores en geometrías reales. Más aún, estos 
modelos han sido usados para comprender el crecimiento e invasión del cáncer 
y en el análisis del tamaño del tumor y su geometría para su aplicación en el 
tratamiento del cáncer y la planificación quirúrgica. La presente revisión intenta 
presentar desde una perspectiva general el uso de modelos basados en 
ecuaciones de reacción difusión no solamente para la descripción del 
crecimiento tumoral en gliomas, con énfasis en procesos tales como 
heterogeneidad tumoral, hipoxia, latencia o necrosis, sino también su uso 
potencial  en el diseño optimizado de terapias específicas al paciente. 
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Introduction. 
Gliomas are primary brain tumors that arise from precursors of glial cells in the 
brain. Among them, glioblastomas are the most aggressive and as it happens 
with most of the gliomas, its growth is so fast and extensive that patients do not 
exhibit any symptoms imposing serious limitations for treatment. Depending on 
its grade, gliomas exhibit internal necrotic regions and a periphery of active tumor 
cells that invades the surrounding tissue. In the case of glioblastomas or high 
grade gliomas, images obtained by contrast enhanced CT or MRI commonly 
resembles the tumor growth as a kind of explosion, i.e., a fast growing front wave 
of very active tumor cells that expands and leaves behind hypoxic, hypoglycemic 
or necrotic tissues. This type of growth can be described by reaction-diffusion 
equations or ballistic growth models, or proliferative-invasive models in the 
biological context. In the following sections several reaction-diffusion models will 
be discussed, how the effect of oxygenation and nutrient concentration has been 
addressed to account for cell hypoxia, tumor dormancy and necrosis, how model 
parameters are extracted from different medical imaging modalities and how all 
this knowledge has led to the proposal of working models to simulate and 
optimize different therapies. 
Reaction-Diffusion Basic Model. 
The first attempts to model glioma tumor growth by means of a reaction-diffusion 
mathematical model [1] were performed by Cruywagen et al. [2], Tracqui et al. [3] 
and Woodward et al. [4] in order to account for the effect of therapies on glioma 
growth and later by Burgess et al. [5] to emphasize the importance of diffusion on 
glioma growth. The model is described by a partial differential equation [1], 
   
𝜕𝑐
𝜕𝑡
= −∇ ∙ 𝐽 + 𝑆(𝑐, 𝑡) − 𝑇(𝑐, 𝑡)   (1) 
where 𝑐 is the tumor cell concentration, 𝐽 is the tumor cellular flux, 𝑆(𝑐, 𝑡) is a 
term that accounts for cellular proliferation and 𝑇(𝑐, 𝑡) represents the 
contribution of treatment. Assuming that the cellular flux obeys Fick’s law, 
𝐽 =  −𝐷∇𝑐    (2) 
and the proliferation term is set to produce an exponential growth, then equation 
(1) leads to 
      
𝜕𝑐
𝜕𝑡
= 𝐷∇2𝑐 +  𝜌𝑐    (3) 
where 𝐷 is a diffusion coefficient that accounts for tumor invasiveness and 𝜌 is 
the tumor cell proliferation rate. The solution of equation (3) is restricted by the 
boundary condition that the flux of cells outside the brain or into the ventricles is 
zero, that is, 
      ?⃗? ∙ ∇𝑐 = 0    (4) 
where ?⃗? is a unitary vector normal to the cortical and ventricular surfaces. 
Experiments performed on rats demonstrated that glioma cells disperse more 
effectively along white matter axon tracts [6-8] than along neuronal cell bodies in 
gray matter, which leads to a variation of equation (3), proposed by Swanson et 
al. [9,10], which includes the spatial dependence of the diffusion coefficient 𝐷, 
   
𝜕𝑐
𝜕𝑡
= ∇ ∙ (𝐷∇𝑐) +  𝜌𝑐   (5) 
To evaluate the differences between grey and white matter motilities, Swanson 
et al. [9,10] used the Fisher approximation [1,11] which stablishes that a travelling 
wave solution of equation (3) propagates with a terminal velocity given by, 
𝑣 = 2(𝜌𝐷)1/2    (6) 
Equation (6) allows for the estimation of the diffusion coefficient knowing the wave 
front propagation velocity and the proliferation rate, 𝜌. Fisher’s approximation 
has been used extensively for parameter extraction of gliomas by Mandonnet et 
al. [12].  Wave front velocities were obtained from the analysis of CT scans [2-
5,12] and finally, assuming a proliferation rate 𝜌 = 0.012 𝑑𝑎𝑦−1, the diffusion 
coefficients can be estimated [9,10] as 𝐷𝑔 = 0.0013 𝑐𝑚
2/𝑑𝑎𝑦, and 𝐷𝑤 = 5𝐷𝑔 =
0.0065 𝑐𝑚2/𝑑𝑎𝑦. Simulations of the glioma growth were performed by Swanson 
et al. [9-10,13-15] on a virtual space using the Brainweb database [16,17], 
assuming a threshold concentration of 8000 𝑐𝑒𝑙𝑙𝑠/𝑚𝑚3 [5],  The results of these 
simulations are shown in Figure 1, where it can be appreciated that tumor 
extension greatly exceeds what is detected by contrast enhanced CT [5], 
depicted as thick black contours. Equation (5) predicts an exponential growth of 
tumor cell concentration, which at longer times achieves a value that is no longer 
realistic or sustainable at cellular level due to the scarcity of oxygen and nutrients. 
This problem can be easily solved by assuming that there is a limit concentration, 
𝑐𝑚, and the proliferative term in equation (5) is changed by a logistic or Verhulst 
growth model, 
   
𝜕𝑐
𝜕𝑡
= ∇ ∙ (𝐷∇𝑐) +  𝜌𝑐 (1 −
𝑐
𝑐𝑚
)  (7) 
From now on, this model is called the Proliferative Invasive model or PI model 
and represents the starting point for the proposal of more realistic models.  
Adding more reality to the model. 
One of the advantages of equation (7) is that it is parametrized with few 
parameters which can be easily extracted from patient data, being the main 
difficulty the computational implementation to solve it on reliable virtual 
environments. Some additional considerations have to be done in order to obtain 
a glioma growth model that takes into account the anisotropy of the diffusion 
tensor, which is particularly relevant in brain tissue, the effect of mechanical 
deformations or mass effect and tumor heterogeneity. 
a) Anisotropy of the Diffusion Tensor. 
The diffusive term in equation (7) not only exhibits a spatial variation depending 
if brain tissue corresponds to either gray or white matter, but it has tensor 
properties as well,  so gray matter is mostly isotropic while white matter is highly 
anisotropic, In the case of white matter, diffusion along the fiber axon tracts is 
1.2 × 10−3 𝑚𝑚2𝑠−1 while it is 0.4 × 10−3 𝑚𝑚2𝑠−1 perpendicularly [18]. 
Taking this fact into account, equation (7) can be rewritten as [19-21], 
   
𝜕𝑐
𝜕𝑡
= ∑ ∑ 𝐷𝑖𝑗
𝜕2𝑐
𝜕𝑋𝑖𝜕𝑋𝑗
𝑗𝑖 + ∑ ∑
𝜕𝐷𝑖𝑗
𝜕𝑋𝑖
𝜕𝑐
𝜕𝑋𝑗
𝑗𝑖 + 𝜌𝑐 (1 −
𝑐
𝑐𝑚
)  
(8) 
for highly anisotropic white matter, and in the case of gray matter which is nearly 
isotropic, i.e., 𝐷𝑖𝑗 = 𝐷𝛿𝑖𝑗, 
𝜕𝑐
𝜕𝑡
= 𝐷∇2𝑐 + ∇𝐷 ∙ ∇𝑐 + 𝜌𝑐 (1 −
𝑐
𝑐𝑚
)  (9) 
which corresponds to the model described by equation (7) where only the spatial 
heterogeneity [9,10] is considered. Simulations were performed by Jbabdi et al. 
[21] using equation (8) and diffusion tensor MRI (DT-MRI) data [22-24]. Since 
DT-MRI only maps the diffusion of water molecules, and tumor cell diffusion along 
white matter axon tracts is likely to be more anisotropic [25,26], some 
assumptions were made to determine tumor cell diffusion in equation (8) starting 
from DT-MRI data, for instance, a scaling factor that preserves the axon tract 
direction but changes the diffusion tensor magnitude and anisotropy. The 
diffusion tensor can be transformed to its diagonal form [27] and can be written 
as, 
?̃?𝑤 = 𝜆1?⃗?1?⃗?1
𝑇 + 𝜆2?⃗?2?⃗?2
𝑇 + 𝜆3?⃗?3?⃗?3
𝑇  (10) 
where 𝜆𝑖 and ?⃗?𝑖  are the eigenvalues and eigenvectors, respectively, of the 
diffusion tensor in the principal axis reference frame. The tensor can also be 
characterized by three indices [27], 𝑐𝑙 , 𝑐𝑝 and 𝑐𝑠, defined in terms of the 
eigenvalues 𝜆𝑖, assuming that 𝜆1 ≥ 𝜆2 ≥ 𝜆3, 
𝑐𝑙 =
𝜆1 − 𝜆2
𝜆1 + 𝜆2 + 𝜆3
 , 𝑐𝑝 =
2(𝜆2 − 𝜆3)
𝜆1 + 𝜆2 + 𝜆3
 , 𝑐𝑠 =
3𝜆3
𝜆1 + 𝜆2 + 𝜆3
 
           (11) 
with 𝑐𝑙 + 𝑐𝑝 + 𝑐𝑠 = 1. Depending on the eigenvalues 𝜆𝑖, the tensor is linear, 
𝑐𝑙 = 1, planar, 𝑐𝑝 = 1, or spherical 𝑐𝑠 = 1, the isotropic case, i.e., gray 
matter. The scaled tensor can be defined as [21], 
?̃? = 𝑎1(𝑟)𝜆1?⃗?1?⃗?1
𝑇 + 𝑎2(𝑟)𝜆2?⃗?2?⃗?2
𝑇 + 𝑎3(𝑟)𝜆3?⃗?3?⃗?3
𝑇 
           (12) 
where, 
[
𝑎1
𝑎2
𝑎3
] = [
𝑟 𝑟 1
1 𝑟 1
1 1 1
] [
𝑐𝑙
𝑐𝑝
𝑐𝑠
]   (13) 
For the simulations, 𝑟 = 10 was used [21]. A more general approach, assuming 
a proportionality between tumor cell diffusion anisotropy and diffusion tensor 
fractional anisotropy was proposed by Painter et al. [28], 
𝑘 =  𝜅 𝐹𝐴(?̃?)    (14) 
With, 𝐹𝐴(?̃?), the fractional anisotropy of the diffusion tensor [22-24,27], defined 
as, 
𝐹𝐴(?̃?) =  
√(𝜆1 − 𝜆2)2 + (𝜆2 − 𝜆3)2 + (𝜆1 − 𝜆3)2
√2(𝜆1
2 + 𝜆2
2 + 𝜆2
2)
 
           (15) 
where 𝜆𝑖 are the diffusion tensor eigenvalues Results of simulations carried on 
real Diffusion Tensor Imaging or DTI are shown in Figure 2, showing a strong 
dependence on the anisotropy enhancement parameter, 𝜅. To evaluate the 
correspondence of actual tumor DT images with the simulations, first Moyasebi 
et al. [29] and later, Swan et al. [30], used the Jaccard index which is a 
measurement of similarity between two finite data sets, i.e. simulated tumor 
growth and actual  tumor DTI, and defined as, 
 𝐽(𝑆𝑇, 𝑇𝐷𝑇𝐼) =
|𝑆𝑇 ∩ 𝑇𝐷𝑇𝐼|
|𝑆𝑇 ∪ 𝑇𝐷𝑇𝐼|
   (16) 
with, 𝑆𝑇 and 𝑇𝐷𝑇𝐼, the simulated tumor and the actual tumor DTI, respectively. 
The Jaccard index was used to optimize tumor growth parameters such as the 
initial starting point, proliferation rates and anisotropy enhancement parameter 
[30]. The initial starting point was determined by computing the Jaccard index for 
simulations starting at different points and selecting the one with the maximum 
value of the index. Similarly, the tumor growth time was determined by computing 
the Jaccard index along the time evolution in a simulation, as shown in Figure 3. 
b) Biomechanical Deformations. 
The first attempt to include mechanical deformations to the glioma growth model 
were introduced by Clatz et al [19,20,31]. They used rheological brain properties 
[32-34] to derive the brain constitutive equation. Tumor growth occurs very slowly, 
so a static equilibrium equation can be proposed for the biomechanical 
deformations, 
∇ ∙ ?̃? + 𝑓𝑒𝑥𝑡 = 0    (17) 
where ?̃? is the internal stress tensor and 𝑓𝑒𝑥𝑡 is the external force. Since the 
growing process is very slow, it can also be assumed that there are linear 
relationships for the constitutive equation and the strain computation, 
     ?̃? = 𝐾𝜖̃    (18) 
     𝜖̃ =
1
2
(∇?̃⃗⃗? + ∇?̃⃗⃗?𝑇)   (19) 
where ?̃? is the elasticity tensor, 𝜖̃ is the linearized Lagrange strain tensor and ?⃗⃗? 
is the tissue displacement. Following Wasserman et al. [35], they proposed a 
modified equilibrium equation to take into account the mechanical impact of the 
tumor growth (mass effect) on the surrounding tissue, with a term proportional to 
the tumor concentration, 𝑐, 
∇ ∙ (?̃? − 𝛼𝑐𝐼) + 𝑓𝑒𝑥𝑡 = 0   (20) 
Some of the results are shown in Figure 4, where it can be appreciated that the 
higher the tumor cell concentration is, shown in Figure 4a, the stronger is the 
mass effect, which corresponds to high tissue displacements or deformations, as 
shown in Figure 4b. More generally, Hogea et al. [36-38] proposed a general 
mass balance equation for the tumor growth,  
     
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) − ∇ ∙ (𝑐?⃗?) +  𝜌𝑐(1 − 𝑐)  (21) 
where the tumor cell concentration has been normalized to the maximum 𝑐𝑚 and 
an advection term has been added which includes a drift velocity, ?⃗? which 
depends on tumor specific mechanisms such as, for example, chemotaxis [36]. 
The stress tensor is defined in a similar way to references [19,20,31], as follows, 
    ?̃? = (𝜆∇ ∙ ?⃗⃗?)𝐼 + 𝜇(∇?̃⃗⃗? + ∇?̃⃗⃗?𝑇)  (22) 
where 𝜆 and 𝜇 are Lame`s coefficients, related to Young`s modulus 𝐸 and 
Poisson’s ratio 𝜐. The equilibrium equation (20) is modified to, 
∇ ∙ ((𝜆∇ ∙ ?⃗⃗?)𝐼 + 𝜇(∇?̃⃗⃗? + ∇?̃⃗⃗?𝑇)) − 𝑓(𝑐, 𝑝)∇𝑐 = 0  
          (23) 
where the proportionality factor, 𝑓(𝑐, 𝑝), is positive and as proposed in 
references [36-38], can be parametrized as, 
𝑓(𝑐, 𝑝) = 𝑝1𝑒
−
𝑝2
𝑐𝑠 𝑒
−
𝑝2
(2−𝑐)𝑠   (24) 
with 𝑝 = (𝑝1, 𝑝2, 𝑠). Equation (24) is a monotonically increasing function in the 
concentration range 0 < 𝑐 ≤ 1 with its maximum at 𝑐 = 1. To complement 
equations (21) and (23), the following set of equations have to be added, 
   ?⃗? =
𝜕?⃗⃗?
𝜕𝑡
      (25) 
   
𝜕?⃗⃗⃗⃗?
𝜕𝑡
+ (?⃗? ∙ ∇)?⃗⃗⃗? = 0    (26) 
where ?⃗⃗⃗? stands for (𝜆, 𝜇, ?̃?). Equations (21), (23), (25) and (26) were used by 
Gooya et al. [39] to perform atlas registration of simulated gliomas with patient 
images, in order to evaluate tumor location, mass effect and degree of infiltration, 
with results shown in Figure 5. 
c) Tumor Heterogeneity, Hypoxia, Necrosis and Angiogenesis. 
The World Health Organization (WHO) grading scheme for gliomas takes into 
account variations in tumor cellularity, mitoses and vascular proliferation. In 
particular, the characteristic vascularity of high grade gliomas, such as 
glioblastomas, and the relation to glioma growth to neo vascularity or 
angiogenesis is a key feature in the modeling of glioma growth [40-42]. Swanson 
et al. [43] proposed a model that included angiogenesis together with hypoxia 
and necrosis in order to quantify the role of angiogenesis in the malignant 
progression of gliomas. The starting equation is given by equation (7) but with 
certain modifications, 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (𝐷(1 − 𝑇)∇𝑐) + 𝜌𝑐(1 − 𝑇) + 𝛾ℎ𝑉 
  −𝛽𝑐(1 − 𝑉) − 𝛼𝑛𝑛𝑐   (27) 
where, 
𝑇 =
(𝑐+ℎ+𝑣+𝑛)
𝑐𝑚
    (28) 
  𝑉 =
𝑣
(𝑐+ℎ+𝑣)
    (29) 
and ℎ, 𝑣 and 𝑛 are the hypoxic, vascular and necrotic cell concentrations, 
respectively. The first two terms in equation (27) account for the dispersion and 
proliferation of normoxic glioma cells, the third corresponds to the conversion of 
hypoxic to normoxic glioma cells, the fourth to the conversion of normoxic to 
hypoxic glioma cells and the fifth to the conversion of normoxic to necrotic glioma 
cells, that depends on necrotic cell concentration through a factor 𝛼𝑛 [44]. Similar 
equations can be written for ℎ, 𝑛 and 𝑣, the hypoxic, necrotic and vascular, 
respectively, 
𝜕ℎ
𝜕𝑡
= ∇ ∙ (𝐷(1 − 𝑇)∇ℎ) − 𝛾ℎ𝑉 + 𝜌𝑐(1 − 𝑉) 
−(𝛼ℎℎ(1 − 𝑉) + 𝛼𝑛𝑛ℎ)   (30) 
with the first term corresponding to hypoxic glioma cell dispersion, the second to 
the conversion of hypoxic to normoxic glioma cells, the third to the conversion of 
normoxic to hypoxic glioma cells and the fourth, to the conversion of hypoxic to 
necrotic glioma cells, 
𝜕𝑛
𝜕𝑡
= 𝛼ℎℎ(1 − 𝑉) + 𝛼𝑛𝑛(𝑐 + ℎ + 𝑣)  (31) 
     
𝜕𝑣
𝜕𝑡
= ∇ ∙ (𝐷𝑣(1 − 𝑇)∇𝑣) + 𝜇
𝑎
𝐾𝑚+𝑎
𝑣(1 − 𝑇) − 𝛼𝑛𝑛𝑣 
          (32) 
where the first term is the dispersal of vasculature, i.e. endothelial cells, 
characterized by a diffusion coefficient 𝐷𝑣 [45], the second corresponds to the 
vasculature proliferation that depends on the concentration of angiogenic factors, 
𝑎, with a maximal proliferation rate 𝜇 [46], and the third term corresponds to the 
conversion of vasculature to necrotic tissue. Finally the equation for the 
angiogenic factors concentration is, 
𝜕𝑎
𝜕𝑡
= ∇ ∙ (𝐷𝑎∇𝑎) + 𝛿𝑐𝑐 + 𝛿ℎℎ − 𝜆𝑎 
    −𝑞𝜇
𝑎
𝐾𝑚+𝑎
𝑣(1 − 𝑇) − ?̅?𝑎𝑣   (33) 
Which includes the diffusion of the angiogenic factors with 𝐷𝑎 [47], the production 
of these factors by normoxic cells [48], at a rate 𝛿𝑐 and by hypoxic cells (VGEF), 
at a rate 𝛿ℎ [49] and its decay with rate 𝜆 [50]. The last two terms in equation (33) 
correspond to the net consumption of angiogenic factors by the vasculature. Main 
results are shown in Figure 6. Notice that as tumor grading increases there is an 
enhancement of normoxic and hypoxic tumor cell concentrations, as well as 
endothelial cell and VGEF concentrations close to the tumor interface, particularly 
for Grade IV gliomas, Figure 6a.  
Some variations to the previous scheme were proposed by Papadogiorgaki et al. 
[51] by assuming a multi-compartmental model of coupled reaction diffusion 
equations, each one related to compartments that are spatially distributed along 
the tumor from its periphery to its inner necrotic core as shown in Figure 7. Each 
compartment is characterized by glioma cell viability and phenotype and, starting 
at the tumor outer interface, there is a proliferative compartment, followed by a 
hypoxic, hypoglycemic and necrotic compartments, all of them embedded in the 
extracellular matrix or ECM, which supplies for oxygen and glucose to the tumor 
compartments and is destroyed by matrix-degradative enzymes or MDEs [52] 
which are secreted by proliferative and hypoxic glioma cells. Increased glucose 
consumption by cancer cells, known as the Warburg effect [53], with 
independence on oxygen levels justifies the inclusion of the hypoglycemic 
compartment in a separate way to the hypoxic compartment [52-55]. The diffusion 
equations for each compartment are, 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (𝐷𝑐(1 − 𝑇)∇𝑐) + ?̃?𝑐(1 − 𝑇) + 𝑔ℎ(1 − 𝑛ℎ)ℎ
+ 𝑔𝑞(1 − 𝑔𝑙𝑞)𝑞 −  𝑏ℎ𝑛ℎ𝑐 − 𝑏𝑞𝑔𝑙𝑞𝑐 − 𝑎𝑛𝑛𝑐 
           (34) 
where ?̃? is a modified proliferation rate that depends on oxygen and glucose 
concentrations [51], 𝑔ℎ, 𝑔𝑞 are the conversion rates from hypoxic and 
hypoglycemic to proliferative, respectively, 𝑏ℎ, 𝑏𝑞, the conversion rates from 
proliferative to hypoxic or hypoglycemic, respectively, and 𝑛ℎ, 𝑔𝑙𝑞 are variables 
that depend on the oxygen and glucose concentration thresholds, such that they 
take the value 0 if the concentration is above the threshold and 1 otherwise, 
finally, as in equation (27), there is a term to account for conversion to the necrotic 
compartment and 𝑇 is similarly defined as in equation (28), 
      𝑇 =
(𝑐+ℎ+𝑞+𝑛)
𝑐𝑚
    (35) 
Similarly, for the hypoxic compartment, 
𝜕ℎ
𝜕𝑡
= ∇ ∙ (𝐷ℎ(1 − 𝑇)∇ℎ) + 𝑏ℎ𝑛ℎ𝑐 − 𝑔ℎ(1 − 𝑛ℎ)ℎ − 𝑎ℎ𝑛ℎ𝑛ℎ
− 𝑎𝑔𝑙ℎ𝑔𝑙ℎ𝑛ℎ − 𝑎𝑛𝑛ℎ 
           (36) 
The last three terms in equation (36) correspond to conversion to the necrotic 
compartment, depending on oxygen and glucose threshold concentrations [51] 
though the coefficients 𝑛ℎ𝑛 and 𝑔𝑙ℎ𝑛, as, 
 𝑛ℎ𝑛 = {
0, 𝛼ℎ ≤ 0.9
1, 𝛼ℎ > 0.9
        𝑔𝑙ℎ𝑛 = {
0,   𝑛ℎ = 1,   𝑔𝑙𝑞 = 0
1,   𝑛ℎ = 1,   𝑔𝑙𝑞 = 1
  
          (37) 
where, 
𝛼ℎ =
ℎ
𝑐+ℎ+𝑞
    (38) 
For the hypoglycemic compartment, 
𝜕𝑞
𝜕𝑡
= ∇ ∙ (𝐷𝑞(1 − 𝑇)∇𝑞) + 𝑏𝑞𝑔𝑙𝑞𝑐 − 𝑔𝑞(1 − 𝑔𝑙𝑞)𝑞 − 𝑎𝑞𝑛𝑞𝑛𝑞
− 𝑎𝑔𝑙𝑞𝑔𝑙𝑞𝑛𝑞 − 𝑎𝑛𝑛𝑞 
           (39) 
and similarly [51], 
𝑔𝑙𝑞𝑛 = {
0, 𝛼𝑞 ≤ 0.75
1, 𝛼𝑞 > 0.75
        𝑛𝑞𝑛 = {
0,   𝑛ℎ = 0,   𝑔𝑙𝑞 = 1
1,   𝑛ℎ = 1,   𝑔𝑙𝑞 = 1
 
           (40) 
with 
𝛼ℎ =
𝑞
𝑐+ℎ+𝑞
    (41) 
Finally, for the necrotic compartment, 
𝜕𝑛
𝜕𝑡
= 𝑎𝑛𝑛𝑐 + 𝑎ℎ𝑛ℎ𝑛ℎ + 𝑎𝑔𝑙ℎ𝑔𝑙ℎ𝑛ℎ + 𝑎𝑛𝑛ℎ + 𝑎𝑞𝑛𝑞𝑛𝑞
+ 𝑎𝑔𝑙𝑞𝑔𝑙𝑞𝑛𝑞 + 𝑎𝑛𝑛𝑞 
           (42) 
The remaining equations are for the oxygen, glucose, ECM and MDE 
concentrations, respectively, 
𝜕𝑜
𝜕𝑡
= 𝐷𝑜∇
2𝑜 + 𝛽𝑜𝑒 − 𝛼𝑜𝑜 − 𝛾𝑐𝑜𝑐 − 𝛾ℎ𝑜ℎ − 𝛾𝑞𝑜𝑞 
           (43) 
𝜕𝑔
𝜕𝑡
= 𝐷𝑔∇
2𝑔 + 𝛽𝑔𝑒 − 𝛼𝑔𝑔 − 𝛾𝑐𝑔𝑐 − 𝛾ℎ𝑔ℎ − 𝛾𝑞𝑔𝑞 
           (44) 
𝜕𝑒
𝜕𝑡
= −𝛿𝑚𝑒    (45) 
   
𝜕𝑚
𝜕𝑡
= 𝐷𝑚∇
2𝑚 + 𝜇𝑐𝑐 + 𝜇ℎℎ + 𝜇𝑞𝑞 − 𝜆𝑚  (46) 
As it is readily seen, models given by [43,51] are extremely detailed and many 
parameters are needed to describe the entire model. A simpler approach can be 
proposed [58,59] where only a reaction diffusion equation is considered, i.e., the 
one associated to tumor normoxic cells, and those compartments related to 
hypoxic, hypoglycemic and necrotic cells are extracted from the original equation 
by certain rules [58,59], depending on tumor cell concentration and glucose 
levels. As the tumor interface progresses, diffusion of nutrients is less effective to 
account for all the cellular energetic requirements, particularly if it attempts to 
remain in a proliferative-invasive state, and as a consequence, for a certain 
nutrient concentration threshold value a transition to a hypoglycemic state occurs, 
and the cell no longer participates in the proliferation-invasion equation for 
normoxic tumor cells. This condition can occur when cell concentrations in a 
surrounding neighborhood around a particular volume element or voxel attain 
almost saturation values 𝑐𝑚, therefore a scarcity of resources is present, and 
there is some effective distance to tumor interface that is related to the diffusion 
length for nutrients (glucose), 𝛿𝐺, that can be estimated from the glucose diffusion 
coefficient 𝐷𝐺  of 5.79 𝑚𝑚
2/𝑑𝑎𝑦 [58]. To evaluate the glucose concentration 
the following parameter is introduced [58,59], 
〈𝑓𝑗〉 =
1
𝑁𝑉𝑅
∑ (1 − 𝑐𝑖)𝑖∈𝑉𝑅 × 𝑒
−
𝑑𝑖𝑗
2
𝛿𝐺
2
  (47) 
where 𝑉𝑅  is a spherical volume of radius 𝑅 > 𝛿𝐺 around the voxel 𝑗, 𝑑𝑖𝑗 is the 
distance between voxels and 𝑁𝑉𝑅 is the total number of voxels inside the volume 
𝑉𝑅 , as defined in Figure 8. The state of each voxel in a three-dimensional 
simulation depends on the values of its concentration 𝑐𝑖 and the parameter 〈𝑓𝑖〉, 
according to Table 1, which shows the transition rules between the different 
compartments. Results of this model are shown in Figure 8. Moreover, the model 
can be further simplified, Patel et al. [61] proposed a simple model, suitable to 
describe high grade gliomas, such as glioblastoma multiforme, that assume only 
two compartments, the proliferative-invasive or normoxic compartment and the 
necrotic compartment, 
𝜕𝑐
𝜕𝑡
= {
∇ ∙ (?̃?∇𝑐) + 𝜌𝑐(1 − 𝑐)     𝑚𝑎𝑥(𝑐) < 𝜏
−𝜂𝑐                                       𝑚𝑎𝑥(𝑐) ≥ 𝜏
 (48) 
where 𝜏 is a threshold for the cellular concentration and 𝜂 is the rate at which 
tumor cell concentration decay exponentially after this threshold is exceeded. 
Both quantities 𝜏, 𝜂 ∈ (0,1) and for the simulations the following values were 
used 𝜏 = 0.85, 𝜂 = 0.90 for best results fitted with patient data [61]. Part of the 
results are shown in Figure 10. 
Simulation of Therapy. 
Treatment of gliomas is commonly initiated by tumor resection, followed by 
radiotherapy and chemotherapy either separately or in combination. The 
reaction-diffusion model was used for tumor resection therapy [4,62,63], 
chemotherapy [3,64,65] and radiation therapy [59,66-75]. Commonly, the effect 
of therapy is included in the differential equation as, 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) − ∇ ∙ (𝑐?⃗?) +  𝑃(𝑐) − 𝑇(𝑐, 𝑡) (49) 
where 𝑇(𝑐, 𝑡) takes into account terms that describe the application of therapy 
or a combination of therapies and exhibits an explicit time dependence according 
to the therapeutic protocol. The tumor growth model is considered in a general 
way including heterogeneous and anisotropic diffusion and advection terms 
combined with a proliferative term 𝑃(𝑐) which can be either exponential, logistic 
or Gompertz. 
a) Tumor resection therapy. 
Tumor resection therapy was simulated as soon as the reaction diffusion model 
for glioma growth was proposed [4] .To account for this kind of therapy within the 
context of the reaction diffusion equation, tumor growth evolution is given by 
equation (49) and separated in two stages: Before tumor resection, which 
depends on tumor initial localization as an initial condition, and after tumor 
resection, assuming that the differential equation is subjected to the following 
condition [62], 
    𝑐(𝑟, 𝑡𝑅) = 𝐹(𝑟)    (50) 
where 𝐹(𝑟) is the remnant distribution of tumor cells once the tumor is resected 
using the detectable tumor cell concentration threshold imposed by contrast 
enhanced CT or MRI, and 𝑡𝑅 is the resection time measured from the time the 
tumor start to grow in the simulation. Frequently, tumor resection therapy extracts 
a spherical tumor volume with an effective radius defined as, 
       𝑟𝑅 = (
3
4𝜋
𝑉𝑅)
1/3
      (51) 
where 𝑉𝑅  is the tumor volume associated to those regions of the tumor cell 
concentration function that fulfill the condition 𝑐(𝑟) ≥ 𝑐𝑅 with 𝑐𝑅, the threshold 
concentration used to assess tumor activity, i.e. defined by contrast enhanced 
CT or MRI. Results are shown in Figure 11 where two aspects have to be 
remarked: tumor recurrence is always expected since the margins defined by the 
detectable tumor cell concentration (typically defined by contrast enhanced MRI) 
do not include regions where disease is present (Figure 11a through Figure 11d, 
and that if tumor resection radius is increased by a 25 % (Figure 11 right side) a 
moderate increase in survival time, just a few weeks, is attained for a survival 
probability of 50 % compared to actual patient data that undergoes gross tumor 
resection [63]. 
 
 b) Chemotherapy. 
Swanson et al. [64] proposed a method to quantify the efficacy of chemotherapy 
under the assumption of homogeneous and heterogeneous drug delivery. For the 
homogeneous case the starting equation is, 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) +  𝜌𝑐 − 𝐺(𝑡)𝑐   (52) 
where 𝐺(𝑡) is a time dependent function defined by, 
    𝐺(𝑡) = {
𝑘,   𝑡 ∈ {𝑇𝑜𝑛}
   0, 𝑡 ∈ {𝑇𝑜𝑓𝑓} 
   (53) 
where 𝑘 is the strength of the action of the therapy drugs upon tumor cells and 
the sets {𝑇𝑜𝑛} and {𝑇𝑜𝑓𝑓} represent the collection of time intervals for which the 
drugs are administered (on) or not (off), respectively. Typically, chemotherapy is 
applied in treatment cycles, each one consists of the administration of drugs for 
a period of time 𝑡𝑐ℎ𝑒𝑚 followed by a waiting period 𝑡𝑤𝑎𝑖𝑡 , meaning that the time 
dependence of 𝐺(𝑡) is an alternating function, periodic in most of the protocols 
used in chemotherapy, during the entire treatment time. The relevant parameter 
to determine the efficacy of the therapy is the ratio 𝛽 = 𝑘/𝜌 [64], which is a 
dimensionless parameter that compares the death rate caused by the drug to the 
proliferation rate, i.e. if 𝛽 > 1, therapy effectively provides tumor control, see 
Figure 12a. In the case of heterogeneous drug delivery, equation (52) holds but 
𝐺(𝑡) now becomes tissue dependent, i.e. gray and white matter, and is defined 
as, 
𝐺(𝑟, 𝑡) = {
{
𝑘𝑊,   𝑟 ∈ 𝑤ℎ𝑖𝑡𝑒 𝑚𝑎𝑡𝑡𝑒𝑟
𝑘𝐺 = 𝛼𝑘𝑊,   𝑟 ∈ 𝑔𝑟𝑎𝑦 𝑚𝑎𝑡𝑡𝑒𝑟
} ,   𝑡 ∈ {𝑇𝑜𝑛}
   0, 𝑡 ∈ {𝑇𝑜𝑓𝑓} 
 
(54) 
where 𝛼 is the ratio of capillary densities between gray and white matter, Figure 
12b, c and d.. A more general model to account for drug delivery heterogeneity 
were proposed by Bratus et al. [65]. The authors assumed a coupled set of 
nonlinear reaction diffusion equations for the tumor cell concentration 𝑐 and the 
drug concentration, ℎ, 
     
𝜕𝑐
𝜕𝑡
= ∇ ∙ (𝐷𝑐2𝛼∇𝑐) + 𝜌𝑐(1 − 𝛽𝑙𝑛𝑐) − 𝐺(ℎ)𝑐  (55) 
    
𝜕ℎ
𝜕𝑡
= ∇ ∙ (𝑑ℎℎ
2𝛼ℎ∇ℎ) − 𝛾ℎℎ + 𝑢(𝑡)  (56) 
where a Gompertz model was assumed for the tumor cell proliferation term in 
equation (55), 𝑑ℎ and 𝛾ℎ are the drug diffusion coefficient and the drug 
elimination rate, respectively, 𝑢(𝑡), which is an explicit time dependent function, 
is the quantity of chemotherapeutic agent administered to the patient during a 
chemotherapy cycle, i.e. 𝑢(𝑡) follows the time protocol established in the 
chemotherapy treatment, and 𝐺(ℎ) is defined as, 
    𝐺(ℎ) =
𝜆ℎ
1+ℎ
     (57) 
For ℎ ≪ 1, equation (57) gives 𝐺(ℎ)~𝜆ℎ, and a linear dependence on the 
chemotherapeutic agent concentration is obtained. At higher concentrations 
chemotherapeutic activity departs from linearity and reaches its maximum 
strength or saturation level, 𝐺~𝜆. 
c) Radiotherapy. 
Radiation therapy is usually modelled by the linear-quadratic or LQ 
radiobiological model [76,77], which assumes that the survival fraction of cells 
subjected to a total dose 𝐷 is given by, 
   𝑆(𝐷) = 𝑒𝑥𝑝(−𝛼𝐷 − 𝛽𝐷2)   (58) 
where 𝛼 and 𝛽 are parameters that characterize the response of tissue to ionizing 
radiation, which is determined by the damage that can be imparted to the DNA 
structure by the radiation. The damage depends on the Linear Energy Transfer 
or LET [76,77] of the ionizing particle (charged particles, neutrons or photons) 
and on which phase of the cell cycle, G2 or mitosis is the cell present. In order to 
avoid toxic effects of the radiation to normal tissue, radiotherapy is usually 
administered in fractions, and a biologically effective dose can be defined [77], 
𝐵𝐸𝐷 = 𝑛𝑑 (1 +
𝑑
𝛼/𝛽
)    (59) 
with 𝑛, the number of fractions and 𝑑, the dose applied per fraction. In this case, 
the survival probability after the fractionated treatment is, 
   𝑆(𝛼, 𝛽, 𝑑(𝑡)) = 𝑒𝑥𝑝(−𝛼𝐵𝐸𝐷)  (60) 
Different schemes can be used for radiotherapy fractionation, 𝑑(𝑡), but typically, 
a fractionation scheme comprises 6 weeks of treatment, 5 days a week with 
weekend interruptions. Also, radiotherapy is a localized therapy, so the fraction 
dose is position dependent and it has to be taken into account during therapy 
simulation. Rockne et al. [67,69], Holdsworth et al. [70], Corwin et al. [72], Elazab 
et al. [74] and Kim et al. [75] proposed a model based on the following equation, 
    
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) +  𝜌𝑐(1 − 𝑐) − 𝑅(𝑑(𝑡))𝑐(1 − 𝑐)  (61) 
where it has been emphasized the explicit time dependence of the fractionation 
scheme, 𝑑(𝑡), and 𝑅(𝑑(𝑡)) is defined as, 
    𝑅(𝑑(𝑡)) = 1 − 𝑠(𝛼, 𝛽, 𝑑(𝑡))   (62) 
and 𝑠(𝛼, 𝛽, 𝑑(𝑡)) is the survival probability after one fraction dose,  
𝑠(𝛼, 𝛽, 𝑑) = 𝑒𝑥𝑝 (−𝛼𝑑 (1 +
𝑑
𝛼/𝛽
))  (63) 
There are two problems in relation to equation (61). The first one is related to the 
tumor cell concentration dependence of the radiation therapy term, i.e., a logistic 
one, which certainly assumes some negative “proliferation rate” given by 
equation (62), and for 𝑐 > 1 , introduces a positive contribution to tumor cell 
concentration, what is nonsense, so the radiation therapy term must be 
exponential with a negative cell death rate, −𝑅. Nevertheless, equation (61) will 
reproduce qualitatively the typical behavior of the tumor size evolution, as shown 
in Figure 13. Additionally, equation (62) represents the cell death fraction due to 
radiation therapy and being a probability, it is a dimensionless quantity, so in 
order to keep all the terms in equation (61) with the same units, Rockne et al. [78] 
proposed that since fractionated radiotherapy is applied on a daily basis, equation 
(62) represents the probability of cell death during a time interval of 1 day and 
can be considered as a probability rate. Although this argument seems to be 
valid, Borasi et al. [73] developed a straightforward method to evaluate the cell 
death rate due to ionizing radiation, starting from the linear-quadratic model. If 
the radiation is applied at a constant dose rate, ?̇?, during a time 𝜏, then according 
to the L-Q model, the cell concentration is, 
𝑐(𝜏) = 𝑐(0)𝑒𝑥𝑝(−𝛼𝑑(𝜏) − 𝛽𝑑(𝜏)2) = 
       𝑐(0)𝑒𝑥𝑝(−𝛼?̇?𝜏 − 𝛽?̇?2𝜏2)   (64) 
where 𝑑(𝜏) is the administered dose at time 𝜏, then, 
1
𝑐(𝜏)
𝜕𝑐(𝜏)
𝜕𝜏
= −(𝛼?̇? + 2𝛽?̇?2𝜏)  (65) 
Taking into account that the irradiation time, ∆𝜏, is very small (of the order of 
minutes) compared to the time interval between fractions (one day), equation (65) 
can be replaced by its mean value over the irradiation time interval, ∆𝜏, so 
equation (61) must be replaced by [73], 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) +  𝜌𝑐(1 − 𝑐) − ?̇?(𝛼 + 𝛽𝑑)𝑐 
         (66) 
Equation (66) is unit consistent and has the correct dependence of the therapy 
term on tumor cell concentration. Nevertheless, if the therapy term is considered 
alone, equation (66) does not recover the survival probability of the L-Q model, 
equation (64), so it must be replaced for one that includes the complete therapy 
term as given by equation (65), 
𝜕𝑐
𝜕𝑡
= ∇ ∙ (?̃?∇𝑐) +  𝜌𝑐(1 − 𝑐) − ?̇?(𝛼 + 2𝛽𝑑(𝑡))𝑐  
           (67) 
Due to the fact that ?̃? and 𝜌 are very small quantities, the temporal evolution of 
the tumor cell concentration imposed by the reaction diffusion terms during the 
time interval of radiation therapy can be considered as negligible, i.e. a suitable 
time interval for numerical integration of equation (67) is 1 day. Integration of 
equation (67) in a time interval very small compared to 1 day yields the correct 
survival probability of the L-Q model. This result allows for decoupling 
proliferation invasion from radiotherapy terms in equation (67) so at the end of 1 
day of time evolution under radiotherapy conditions, tumor cell concentration is, 
𝑐(1 𝑑𝑎𝑦) = 𝑐𝑃𝐼(1 𝑑𝑎𝑦)𝑆(𝛼, 𝛽, 𝑑)  (68) 
with 𝑐𝑃𝐼, the tumor cell concentration obtained from the proliferation invasion 
model. This approach has been used by Rojas et al. [59] and Unkelbach et al. 
[79,80] for high grade gliomas and by Henares-Molina et al. [81] for low grade 
gliomas. 
The other aspect that has to be considered simulating radiation therapy is that it 
is a localized therapy and tumor delineation is very important for the therapy to 
be effective. Using the reaction diffusion model for glioma growth, Konukoglu et 
al. [82] demonstrated that the tumor cell concentration falls approximately in an 
exponential way depending on the distance, |𝑟|, measured from the detectable 
tumor interface, i.e., defined by contrast enhanced MRI, 
𝑐(|𝑟|) ∝ 𝑒𝑥𝑝 (−
|𝑟|
𝜆𝑇
)    (69) 
where 𝜆𝑇 is defined as the infiltration length and depends on the particular tissue, 
grey or white matter. It is related to the model parameters by, 
𝜆𝑇 = √
𝐷𝑇
𝜌
     (70) 
Clearly, the infiltration length for white matter is bigger that the infiltration length 
for grey matter, 𝜆𝑊~√𝐷𝑊/𝐷𝐺. Equation (70) allows for an improved tumor 
delineation using the infiltration length or multiples of it to establish a safety 
margin for the prescribed dose to be applied [80]. The estimation of subthreshold 
tumor based on the PI-DTI growth model has been proposed by Hathout et al. 
[83] as a tool for tumor delineation in radiation therapy planning. Unkelbach et al. 
[79] developed a treatment planning method that determines the cumulative dose 
𝐷, distributed in 𝑛 fractions, which minimizes the survival probability within the 
tumor lesion, expressed as, 
𝑆(𝛼, 𝛽, 𝑑) = 𝑒𝑥𝑝(−𝛼𝐷(1 + 𝜅𝐷)) ≈ 𝑒𝑥𝑝(−?̅?𝐷)  
         (71) 
where 𝜅 = 𝛽/𝛼𝑛, ?̅? = 𝛼(1 + 𝜅𝐷𝑃), the effective radiosensitivity, and 𝐷𝑃 is the 
average prescription dose over the tumor lesion. The optimization problem is 
formulated as follows [79]. The integral cell survival,  
  𝑓(𝐷, 𝑐) = ∑ 𝑐𝑖𝑒𝑥𝑝(−𝛼 ̅𝐷𝑖)𝑖∈𝑉𝐿    (72) 
is minimized subject to the condition, 
1
𝑁
∑ 𝐷𝑖𝑖∈𝑉𝐿 ≤ 𝐷𝑃   (73) 
The sums are performed over all the voxels 𝑖 within the tumor lesion volume, 𝑉𝐿. 
The optimal solution is obtained by looking at the stationary points of the 
Lagrange function [79], 
𝐿 = ∑ 𝑐𝑖𝑒𝑥𝑝(−?̅?𝐷𝑖)𝑖∈𝑉𝐿 + 𝜇(∑ 𝐷𝑖𝑖∈𝑉𝐿 − 𝑁𝐷𝑃) (74) 
where 𝜇 is the Lagrange multiplier and is given by [79], 
    
1
?̅?
𝑙𝑛 (
?̅?
𝜇
) = 𝐷𝑃 −
1
?̅?𝑁
∑ 𝑙𝑛(𝑐𝑖)𝑖∈𝑉𝐿   (75) 
Results imposing the dose restrictions, given by equation (73), and the infiltration 
length dependence, given by equation (69), are shown in Figure 14. This 
approach has recently used by Lê et al. to establish a personalized treatment 
planning [84]. These results are applicable to define an optimal treatment 
planning and can be modified depending on the treatment specifics, i.e., single 
fraction or multifractioned treatment, IMRT or VMAT, and it minimizes the survival 
probability of the tumor lesion. In order to maximize the patient’s survival 
probability, it is necessary to simulate a collection of virtual patients, all of them 
prepared with parameters derived from the actual patient, and subject them to 
the selected therapy. The patient’s survival probability is then obtained by a 
Kaplan-Meier analysis [85] over the simulated course of the therapy. Rojas et al. 
[59,86] developed a method to estimate the effect of therapy over the patient´s 
survival probability, using the multi compartmental tumor growth model described 
in [58,59] and assuming additional transition rules imposed by the therapy, as 
shown in Table 2. Radiotherapy was considered as in equation (68), with a 
survival probability 𝑆(𝛼, 𝛽, 𝑑) according to Table 3, depending if the tissue is 
normoxic, hypoxic or hypoglycemic. Results are shown in Figure 15. 
Conclusions. 
It has been shown that the proposition of a reaction diffusion model, starting from 
the basic proliferative-invasive Murray-Swanson model, to more detailed models 
that include brain anisotropy, tumor heterogeneity and biomechanical 
deformations, contributed in a significant way to support a working model suitable 
for simulation of patient specific therapy. Contributions, particularly in the area of 
chemotherapy and radiation therapy are very promising and possibly in a very 
near future will be available as routine methods in treatment planning and therapy 
optimization.    
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Tables. 
Table 1. Voxel classification, thresholds and transition rules [59] 
Class Description Threshold values Transitions 
1 Proliferative-invasive state 𝐷 > 0, 𝑐 < 0.9 1 → 2 
2 
Proliferative-invasive  and 
hypoxic state (reversible) 
𝐷 > 0, 𝑐 ≥ 0.9 2 → 1∗, 2 → 3 
3 
Hypoglycemic state 
(reversible) 
〈𝑓〉 ≤ 0.02 3 → 2†, 3 → 4 
4 Necrotic state (irreversible) 〈𝑓〉 ≤ 0.006 - 
Reversibility occurs: *If tumor cell concentration drops to 𝑐 < 0.9, or †if  〈𝑓〉 >
0.02 , due to fluctuations in the growth model only. 
 
 
Table 2. Comparison of transition rules [86] 
Class Description Without therapy With therapy 
1 Normoxic 1 → 2 1 → 2 
2 Hypoxic 2 → 1∗, 2 → 3 (2 → 1∗), 2 → 3 
3 Hypoglycemic 3 → 2†, 3 → 4 (3 → 2†), (3 → 4) 
4 Necrotic - - 
Reversibility occurs: *If tumor cell concentration drops to 𝑐 < 0.9, or †if  〈𝑓〉 >
0.02 , due to fluctuations in the combined growth and therapy model. Transitions 
within parenthesis are enhanced by therapy. 
 
Table 3. Survival probability per fraction dose, 𝑆(𝛼, 𝛽, 𝑑) [86] 
Class 𝑆(𝛼, 𝛽, 𝑑) 
1 0.83 [87] 
2 0.90 
3 0.99 
 
 
 
 
 
Figure captions. 
Figure 1. Axial views of a glioma growth simulation using the proliferation invasion 
model or PI model at the time of diagnosis, left, and death, right, for an initiation 
site in frontal lobe, indicated by an asterisk. Color is associated to tumor cell 
concentration: red stands for high concentration and blue for low concentration. 
Black contour denotes the detection threshold by enhanced CT. Simulation 
elapsed time for diagnosis is 158 days and for death, 256 days. Adapted from 
[13,14]. 
Figure 2. Simulations using the PI-DT model performed on actual patient DT 
fractional anisotropy images. The anisotropy enhancement parameter 𝜅, is zero 
for the isotropic case, shown on top. Adapted from [28]. 
Figure 3.  Dependence of the Jaccard index with the tumor evolution time. The 
maximum in the graphic indicates when there is a match between the simulated 
and real tumors, allowing for assessment of tumor time and possibly tumor 
grading. Simulations, shown on the right, are represented over fractional 
anisotropy maps. The outline of the simulated tumor is represented in white while 
the detected tumor outline is represented in black. Adapted from [30]. 
Figure 4. Effect of biomechanical deformations, (a) Glioma growth simulation 
including diffusion tensor anisotropy and biomechanical deformations. (b) Brain 
tissue displacements induced by the tumor mas effect. In both graphics color 
indicates, red, highest tumor cell concentration or displacement and blue, for the 
lowest. Adapted from [19,20,31]. 
Figure 5. Tumor growth simulations on atlas space (right) registered on T1 
reference images (left). Adapted from [39]. 
Figure 6. Results of simulations using equations (27-33). (a) Concentration 
profiles for different glioma grades. (b) Survival time as a function of 𝐷 and 𝜌. 
Adapted from [43]. 
Figure 7. Multi-compartmental model proposed by reference [51]. Compartments 
are C, proliferative or normoxic, H, hypoxic, Q, hypoglycemic and N, necrotic.  
Figure 8. Search sphere used to determine nutrients concentration threshold for 
latency and necrosis states. Adapted from [59]. 
Figure 9. Seven years’ time evolution for a virtual high grade glioma. On the left, 
distribution of tumor classes, according to Table 1, represented in color: red, class 
2, yellow, class 3 and black, class 4. Right, time evolution of the number of voxels 
for each class. Adapted from [59]. 
Figure 10. Comparison of simulated GBM tumor progression models for a time 
period over 30 days with actual tumor images. (a) Observed tumor images, (b) 
simulation assuming anisotropic diffusion, without necrosis and (c) simulation 
assuming anisotropic diffusion with necrosis. Color indicates tumor cell 
concentration being red to denote the highest and violet for the lowest. Adapted 
from [61]. 
Figure 11. Simulations on tumor resection therapy. Left, (a) tumor concentration 
distribution defined by the condition 𝑐(𝑟) ≥ 𝑐𝑅 at the resection time 𝑡𝑅, (b) 
remnant tumor concentration distribution, 𝐹(𝑟), immediately after resection (c) 
detectable tumor concentration distribution, 𝑐(𝑟) ≥ 𝑐𝑅, 160 days after resection 
and (d) complete tumor concentration distribution function. Right, survival curves 
after resection: Actual patients subjected to gross total resection (GTR, 
asterisks), simulated patients subjected biopsy and no resection (BX/STR 
squares), simulated patients total resection of a volume defined by contrast 
enhanced MRI, with radius 𝑟𝑇1 (GTR, circles) and simulated patients with total 
resection for 1.25𝑟𝑇1. Adapted from [62,63]. 
Figure 12. Efficacy of chemotherapy. (a) Size of the detectable tumor region as 
a function of time for different values of the parameter 𝛽, (b) A T2-weighted 
equivalent map at the time of initiation of chemotherapy, (c) six weeks after the 
end of the chemotherapy cycles and (d) 30 weeks after (b). Notice the recurrence 
of disease. Adapted from [64]. 
Figure 13. Typical behavior of the time evolution of tumor size during radiation 
therapy. Blue line indicates tumor size evolution without therapy and red line with 
therapy. Arrows indicate (a) beginning and (b) end of the therapy, respectively. 
Figure 14. Dose distributions that minimize tumor cell survival probability. Colors 
represent dose in Gy. Adapted from [79,80]. 
Figure 15. Simulations of radiotherapy for high grade gliomas. (a) Collection of 
untreated virtual patients with initiation point randomly selected in the right frontal 
lobe. (b) Tumor volume evolution with time. Different curves correspond to the 
application of therapy at different virtual years, characterized by a drop in the 
tumor volume. Vertical dashed line indicates the time when the untreated tumor 
reaches a volume that causes virtual patient death. (c) Survival probability 
obtained by a Kaplan-Meier analysis; thin continuous and dashed lines 
correspond to untreated tumors, thick continuous line corresponds to treatment.  
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